ProKidney Q3 net loss $33.9M; cash $506.3M; Phase 3 REACT trials on track

PROKIDNEY CORP.

Cash and equivalents of $506.3M as of Sept 30, 2022, up from $20.6M at Dec 31, 2021, after $596.5M gross proceeds from business combination.
Net loss before noncontrolling interest of $33.9M for Q3 2022 vs $17.1M in Q3 2021; R&D expenses $21.1M vs $14.7M.
Phase 3 proact 1 enrolling up to 600 subjects; first interim data expected Q4 2024; proact 2 enrollment to begin Q1 2023.
Phase 2 REGEN-007 expanded to 50 subjects; interim data expected mid-2023.
Received UK MHRA allowance and positive EMA scientific advice for Phase 3 program supporting eventual MAA.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PROKIDNEY CORP. reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 14, 2022, ProKidney Corp. issued a press release to announce the financial results of ProKidney LP and its subsidiaries for the third quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

PROKIDNEY CORP. filing history →

Source: SEC EDGAR

accession 0000950170-22-024799

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.